420 with CNW — DeSantis Reaffirms Opposition to Federal Cannabis Legalization

Ron DeSantis, the Florida governor and a contender for the 2024 presidential election on the Republican ticket, has restated his firm stance against the legalization of marijuana if he were to assume office. His argument asserts that the legalization of marijuana has contributed to the growth of the illegal market in Colorado — despite evidence to the contrary.

While engaging with supporters during a campaign event in Iowa over the weekend, a concerned attendee shared stories of individuals whose children had developed cannabis-induced psychosis. The individual queried DeSantis about his position on legalizing or rescheduling cannabis at the federal level should he ascend to the presidency. DeSantis responded, reiterating his unwavering stance against legalization, echoing viewpoints he had expressed in a similar vein back in June.

The conversation then shifted toward a broader discourse on the negative consequences of substance abuse. DeSantis highlighted the existence of an unregulated drug market in San Francisco, using it as an example to underscore his belief that prevailing policies have contributed to the deterioration of society by enabling drug use.

DeSantis acknowledged the existence of medical cannabis access in Florida through a voter-approved constitutional amendment. However, he emphasized that different states have handled cannabis regulation differently, and he expressed his disinclination to further increase its accessibility under his leadership.

The fate of cannabis legalization in Florida might not solely rely on DeSantis’s stance, as the state Supreme Court is currently deliberating on the inclusion of a marijuana legalization initiative on the 2024 ballot.

Although DeSantis didn’t substantiate his argument with data or references, various government and private analyses suggest that Colorado has witnessed a considerable reduction in illicit market influence since implementing legalization. Notably, a report by Whitney Economics and Leafly from the previous year indicated that the regulated industry accounts for 99% of adult-use cannabis sales in Colorado, signifying a successful transition from the illicit market.

Recent data from the city of Denver further bolstered the case for legalization. The report indicated a significant decrease in law enforcement’s handling of illegal marijuana in 2022, providing tangible evidence of legalization’s effectiveness in curbing illicit sales.

DeSantis’s opposition to marijuana legalization, despite a growing bipartisan trend in support of reform, is consistent with his historical stance. This standpoint is only one aspect of his multifaceted position on the matter, as he competes to maintain his position as the second-leading candidate in the Republican presidential nomination race.

On a policy level, DeSantis signed a bill that recently came into effect in Florida, imposing stricter regulations on medical marijuana advertising and manufacturing. The law prohibits any promotional content related to “recreational” marijuana use while also imposing more rigorous eligibility criteria for individuals working in the cannabis industry. Additionally, DeSantis signed a bill in June that prevents residents of sober living facilities from possessing or using medical marijuana, even if they possess a doctor’s certification for therapeutic use. This restriction does not extend to other doctor-prescribed medications.

In the same month, the governor enacted legislation prohibiting the sale of consumable hemp products, including cannabis-infused chewing gum, to individuals under the age of 21. This expanded the existing restriction on the purchase of smokable hemp by young individuals.

DeSantis’ opposition to federal cannabis legalization suggests that it may still take a while for politicians on Capitol Hill to enact federal drug policy reforms that align with the wishes of the people, just in the same way that the current U.S. president hasn’t pushed for major reforms as had been expected when he was elected. Countrywide cannabis legalization as enjoyed by companies such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) in Canada is still a dream for American enterprises.

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Survey Shows Patients Satisfied with Marijuana as Neuropathy Treatment

A recent survey has found that marijuana is equally effective in alleviating neuropathy symptoms as opioids, raising questions about the validity of previous studies that utilized government-grown cannabis with lower potency. The survey was conducted by NuggMD, a company that connects patients with medical marijuana recommendations, and it involved 603 participants who used marijuana primarily or secondarily for neuropathy.

In the study, neuropathy, a painful condition, was measured by patients who assessed their pain levels on a scale of 1 to 10 both prior to and after using marijuana as a remedy. The outcomes were promising, indicating considerable relief. The average pain score prior to using cannabis was 7.64, and it decreased to 3.44 after consumption, resulting in an average pain relief of 4.2 out of 10.

These findings were on par with or even better than conventional treatments such as prescription opioids, as demonstrated by previous research. For instance, a 2017 trial illustrated that acetaminophen and oxycodone, acetaminophen and ibuprofen, acetaminophen and codeine, and acetaminophen and hydrocodone provided pain relief scores of 4.4, 4.3, 3.9 and 3.5, respectively.

Only 10 states explicitly recognize neuropathy as a qualifying condition for medical cannabis.

The researchers also noted that although increasing cannabinoid dosages didn’t consistently lead to greater relief, patients generally benefitted from higher-potency marijuana containing over 20% THC. This observation might explain the discrepancy between NuggMD’s findings and previous studies that employed lower-THC marijuana.

Among the surveyed patients, the majority (58.6%) used cannabis flower with THC exceeding 20%. Fewer participants used concentrates (26.3%), sub-20% THC flower (11.1%), or noninhalable products (3.9%). In essence, patients who found cannabis effective predominantly chose high-potency products, which are widely available and notably more potent than research-grade government cannabis.

The study’s authors highlighted that the consistency lay in the use of high-potency marijuana with 20% or higher THC. They pointed out that much of the pain-relief research used cannabis products with less than 20% THC, leading to claims that THC isn’t effective for pain relief.

Until recently, federally sanctioned marijuana research solely utilized cannabis from a DEA-authorized farm, which was widely criticized for its quality. This research monopoly was disrupted when the DEA approved additional growers, offering a more diverse range of cannabis strains.

However, NuggMD’s findings imply that prior neuropathy studies might have been compromised due to low-THC products. Lawmakers have voiced concerns about researchers’ limited access to cannabis that resembles what’s actually available in dispensaries. Efforts to change this policy have advanced in Congress but have yet to pass. Despite President Joe Biden’s move to ease marijuana research last year, the final bill didn’t include provisions for scientists to acquire retail cannabis.

NIDA Director Nora Volkow also highlighted that this restriction, combined with cannabis’s Schedule I classification, has hindered comprehensive research into its benefits and risks.

The NuggMD study doesn’t establish causal evidence of cannabis’s efficacy in treating neuropathic pain but underscores patients’ preference for medical marijuana over alternative treatments. When asked about their choice if they lacked access to medical cannabis, most respondents were inclined to tolerate symptoms (128) or use alcohol (36) rather than opt for opioids (112).

This survey suggests that patients aren’t just buying medical cannabis products from enterprises such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) as part of a fad. The patients keep using those products because they experience relief from their symptoms.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

NECANN’s New York Cannabis & Hemp Convention Set to Empower the Cannabis Industry

Investors, business executives, researchers, and industry leaders, are invited to attend NECANN’s New York Cannabis & Hemp Convention to be held in Albany, New York from September 29 – 30, 2023. The highly anticipated event will focus on the latest trends in the cannabis and hemp industry. The convention serves as a unique platform to connect with industry leaders and explores the limitless possibilities within the cannabis and hemp sectors.

Featuring thought-provoking exhibits and engaging sessions, the New York Cannabis & Hemp Convention is designed to create a lasting impact on the participants. The immersive atmosphere will encourage attendees to share their experiences and gain valuable insights. As a perfect blend of opportunity, passion, and creativity, the two-day event will feature leading brands from different parts of the cannabis and hemp industries. Attendees will get an opportunity to explore a wide range of products.

Shaping the Cannabis and Hemp Industries

The main highlight of the convention is knowledge sharing. Keynote speakers and industry experts will take insightful seminars to discuss the latest trends and innovations in the industry. The thought-provoking panel discussions will provide a glimpse into the latest innovations in the industry. Attendees will get an opportunity to learn about industry trends, cannabis regulations, medical innovations, and investment opportunities.

The New York Cannabis & Hemp Convention will showcase the transformative potential of hemp across different industries, including food, textiles, construction, and beverages. It will enable participants to foster a collaborative environment that reveals innovative ideas and the latest advancements in the hemp industry. Attendees will get a golden opportunity to share their experiences, challenges, and stories, while ensuring an equitable cannabis landscape.

To learn more, please visit https://cnw.fm/CNM8x. 

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Judge Says NJ Police Officer Sacked for Marijuana Use Should Get Job Back

The cannabis-reform movement recently scored a win after a New Jersey administrative law judge ruled that another police officer who was fired for marijuana use must be reinstated. Administrative Law Judge Joann Lasala Candido ruled in favor of terminated police officer Omar Polanco last week.

Even though the Jersey City Police Department consented to New Jersey’s off-duty cannabis use policy that allowed even law enforcement to use cannabis during off-duty hours, the police department has fired multiple officers for testing positive for THC metabolites. However, the Civil Service Commission and two administrative law judges have now overruled the department’s decision in line with constitutional protections issued by New Jersey’s 2021 cannabis legalization law.

In addition to Candido’s ruling, earlier this month the state Civil Service Commission (CSC) and Administrative Law Judge Kimberly Moss ruled that the police department violated state law by firing officer Norhan Mansour for failing a THC test. Jersey City PD now has orders to reinstate both Mansour and Polanco with backpay, a major blow to both the city’s mayor and police chief.

Jersey City Mayor Steven Fulop has expressed opposition to the policy granting cannabis access to marijuana during off-duty hours and said that it would put law enforcement at risk of operating with impaired judgment.

In both Polanco’s and Mansour’s cases, Jersey City argued that federal laws banning “unlawful marijuana users” from possessing or buying firearms preempted the state’s cannabis laws. However, the judges specified that the rule did not apply to police as they could receive firearms after completing police academy training.

Like the two judges, the Civil Service Commission did not buy into the city’s argument, calling it “unpersuasive” and without the support of facts. The commission added that the department’s talking point about the federal ban on firearm purchases for marijuana consumers did not apply to police officers because they don’t have to fill out the federal form asking them to declare their cannabis use before they can obtain a firearm. Furthermore, the commission said that the police department’s actions were unjustified, reversed the termination and approved Norhan Mansour’s appeal.

Mansour’s lawyer Peter Paris likened Jersey City’s actions to firing a police officer for having a beer off-duty, only this case was much worse because New Jersey residents have the constitutional right to consume cannabis.

It is still unclear whether the three other Jersey City law enforcement officers who were terminated for positive THC tests and sued the city police department will have similar positive outcomes. However, these decisions by the courts in New Jersey to assert that police officers can consume marijuana while they aren’t on duty will likely allow members of the armed forces to indulge in state-legal marijuana. As this happens, demand for products sold by licensed entities such as Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) will grow.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Suggests Minor Cannabinoids Could Treat Skin Ailments

Recent research suggests that lesser-known cannabinoids derived from marijuana and hemp, such as CBN, CBM, CBC, CBDV and THCV, might hold promise in treating dermatological conditions INCLUDING acne, psoriasis and eczema. The study, published recently in the peer-reviewed journal “Molecules,” highlights the potential therapeutic value of these minor cannabinoids in managing skin disorders as well as presenting new avenues for patient care and well-being enhancement.

The research, led by Polish scholars Dorota Kowalczuk and Emilia Kwiecień, involved an extensive review of existing scientific literature. The team observed that minor cannabinoids exhibit a range of pharmacological activities, encompassing anti-itch, analgesic, antimicrobial and anti-inflammatory properties. These cannabinoids have also shown efficacy in alleviating symptoms linked to various dermatological issues, including pruritus, acne, eczema and psoriasis.

Some minor cannabinoids appeared particularly suited for targeting specific skin conditions. For instance, CBDV, due to its anti-inflammatory characteristics, can potentially soothe itching and inflammation related to atopic dermatitis. Additionally, its antioxidant properties could aid in healing acne lesions.

Similarly, other recently identified cannabinoids such as CBE and CBM display anti-inflammatory potential and open new avenues for research into targeted disease conditions. CBC, known for its anti-inflammatory and antioxidant effects, may offer benefits for treating psoriasis, acne and atopic dermatitis.

THCV stands out for its potential in combating acne because it appears to regulate sebum production. Its anti-inflammatory and antibacterial attributes contribute to alleviating inflammation and targeting bacteria linked to acne development.

The researchers highlighted the therapeutic potential of minor cannabinoids, including cannabinol (CBN), cannabigerol (CBG), cannabigerolic acid (CBGA), tetrahydrocannabivarin (THCV), cannabichromene (CBC), cannabidiforol (CBDP) and cannabidivarin (CBDV), as well as newer discoveries such as cannabielsoin (CBE) and cannabimovone (CBM).

The effects are believed to stem from interactions between cannabinoids and the body’s endocannabinoid system, a central regulatory mechanism crucial for maintaining organism health and function. This system plays a pivotal role in regulating skin functions, immune responses, cell differentiation, proliferation and survival, thereby effectively mitigating skin inflammation. Furthermore, topical application of these minor cannabinoids may hold promise for mitigating aging-related effects on the skin.

However, the researchers caution that more in-depth research is essential to validate their safety and effectiveness. Multiple challenges, including impact on the nervous system, product quality and regulation concerns, and ethical and legal considerations, need comprehensive exploration.

They concluded that despite the encouraging therapeutic potential, the utilization of cannabinoids, particularly minor ones, requires continued research, stringent regulations and a balanced approach to maximize benefits while minimizing any potential risks to health and society.

Companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) selling marijuana for both medical and recreational use could be helping people combat more symptoms or conditions than the patients themselves intend.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes What Is Considered One Of America’s Most Serious Health Problems

  • The ADA reports that 37.3 million Americans had diabetes in 2019, and the number has been growing by an average 1.4 million each year95% of Americans with diabetes are diagnosed with type 2 diabetes, which can lead to heart disease, stroke, kidney damage, and nerve damage when left untreatedLexaria’s DIAB-A22-1 pre-clinical diabetes study using DehydraTECH(TM)-CBD in obese diabetic-conditioned animals shows promising results, prompting the company to investigate for human trial

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its intent to conduct a human clinical trial to examine its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for diabetes control and weight loss. The company’s pre-clinical diabetes study, DIAB-A22-1, in obese diabetic-conditioned animals, provided successful results and has driven Lexaria’s management to investigate whether animal improvements will be evidenced in humans.Diabetes can impact various parts of the body, including the heart, kidneys, eyes, feet, and legs. The longer a person lives with the condition at high blood sugar levels, the more serious complications can become. Diabetes is manageable, but its impact on overall health is often underestimated.According to the American Diabetes Association (“ADA”), 37.3 million Americans reported having diabetes in 2019. Of those 37.3 million, 28.7 million were diagnosed, and 8.5 million were not. Each year, the ADA reports an additional 1.4 million Americans are diagnosed with diabetes (https://cnw.fm/5ZFeZ). When left untreated, diabetes can lead to complications, including heart disease, stroke, kidney damage, and nerve damage. “Non-alcoholic fatty liver disease (‘NAFLD’), which doctors historically have diagnosed in adults, is rapidly increasing in children, driven by the obesity epidemic” (https://cnw.fm/ImCtn).More than 95% of the people diagnosed with diabetes fall into the category of Type 2 diabetes, which affects how the body uses sugar for energy. Over time, type 2 diabetes can cause serious damage to the body if it is not managed. Often preventable, factors that contribute to the development of type 2 diabetes are obesity, lack of exercise, and genetics (https://cnw.fm/sgqWK).Lexaria designed DehydraTECH for formulating and delivering lipophilic drugs and active pharmaceutical ingredients. The benefits of DehydraTECH include faster drug delivery times, increased bioavailability, increased brain absorption, higher drug potency, reduced drug administration costs, masking tastes, and reduced use of sugars.DehydraTECH is suitable for various product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, topicals, and over-the-counter pills, capsules, tablets, and oral suspensions. Lexaria has already shown value in the hypertension and nicotine pouch industries through the use of its DehydraTECH formulations.Lexaria’s DIAB-A22-1 study in obese diabetic-conditioned animals utilized its DehydraTECH-CBD formulation, which showed an ability to reduce animal blood sugar levels – warranting additional investigation. Lexaria reported:

  • Lowered blood glucose levels by 19.9% (p<0.05)Lowered overall body weight by 7% sustained over eight weeksWitnessed a statistically significant increase in locomotor activity (p<0.05)Lowered triglyceride levels by more than 25% (p<0.007)Lowered blood urea nitrogen levels by 27.9% (p<0.001)

The company is very interested in discovering if a similar formulation might effectively control human blood sugar levels – strongly suggesting that DehydraTECH-CBD may be a potential solution for treating diabetes and its complications in humans.Lexaria intends to conduct the study, which is currently being designed, at the same medical research hospital in Europe that it used for its recent human clinical hypertension studies. The cost-effective approach allows Lexaria to complete the most research possible at a fraction of the cost of US-based registered study programs. Once the study has been designed and approved, Lexaria will provide additional information, including timelines and study details, as they become available.For more information, visit the company’s website at www.LexariaBioscience.com.NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXXAbout CannabisNewsWireCannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)For more information, please visit https://www.CannabisNewsWire.comPlease see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/DisclaimerCannabisNewsWireDenver, COwww.CannabisNewsWire.com303.498.7722 OfficeEditor@CannabisNewsWire.comCannabisNewsWire is powered by IBN

420 with CNW — Marijuana Legalization Voter Initiative Text Gets Nod from Ohio Officials

Officials in Ohio have approved language for a measure that would appear on the November 2023 ballot giving voters the chance legalize marijuana in the state. The Ohio Ballot Board unanimously approved a recently drafted and certified summary from the secretary of state’s office in a meeting that saw no discussion of the legislation’s text or testimonies from supporters and opponents.

State officials announced two weeks ago that the activists behind the Ohio cannabis legalization measure had collected enough valid signatures to qualify the proposed legislation for the November ballot. A statement from Secretary of State Frank LaRose’s office revealed that the Coalition to Regulate Marijuana Like Alcohol (CTRMLA) ultimately submitted 127,772 valid signatures, around 3,000 more than the number required by state law.

The summary approved by the Ohio Ballot Board indicated that the proposal would legalize and regulate cannabis cultivation, processing, purchasing, home cultivation and consumption by adults aged 21 years and older. It would also allow the possession of up to 15 grams of cannabis concentrates, up to 2.5 ounces of cannabis, cultivation of up to 6 cannabis plants for one individual’s personal use, and up to 12 plants max per home.

Furthermore, the summary stated that the measure would require the formation of a Division of Cannabis Control to regulate and penalize recreational cannabis operators, testing laboratories and people who require cannabis-related licenses. It also noted that the adult-use cannabis measure would create a social equity program, sustain landlords’ and employers’ rights to ban cannabis use in specific circumstances, and tax cannabis sales revenue.

The measure would channel cannabis tax revenue to different accounts, offer protections for financial institutions that serve licensed cannabis businesses and protect the identities of individuals taking part in the recreational cannabis market.

CRMLA spokesperson Tom Haren noted in a recent statement that the measure would provide hundreds of millions of dollars in new tax revenue and the same level of regulation seen in the medical marijuana market. According to Haren, the campaign is looking forward to eliminating Ohio’s cannabis black market once official sales begin.

Since cannabis has been the most consumed illegal drug in the United States for years, a massive black market is supplying the country’s immense demand for marijuana. Even now that more than 20 states have recreational cannabis markets, America’s illicit cannabis market still supplies most of the country’s cannabis, undercutting state-legal adult-use programs, funding criminal enterprises and harming the environment.

If Ohio voters choose to legalize cannabis in the upcoming ballot vote, the legal recreational market will likely have a hard time competing with the illicit market. However, major cannabis players, such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), in different markets have always found a way to attract customers, so the licensed players in Ohio will thrive as best they can once the recreational market launches.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — DOJ Asks FBI to Investigate Itself After Cannabis Arrest Data Errors Are Found

After more than a year, a watchdog from the Justice Department responded to a lawyer’s concerns about issues in how the FBI gathers and reports data related to marijuana possession arrests. The response, however, was not a direct addressing of the problem but a suggestion that the FBI should internally investigate the matter.

Eric Sterling, a lawyer known for his work in drug-policy reform and a former congressional aide, sent a letter to the Department of Justice’s Office of the Inspector General in May last year. In his letter, Sterling highlighted a situation where a police department in Maryland was categorizing citations for cannabis possession under the state’s decriminalization law as arrests. This data was being shared with the FBI, potentially leading to skewed statistics and a distorted view of law enforcement’s focus and the implementation of legalization and decriminalization policies.

Sterling, an appointed member of the Policing Advisory Commission for Montgomery County, Maryland, urged the DOJ inspector general’s office to initiate a formal investigation into this matter.

After approximately 14 months, the OIG investigations division responded to Sterling’s inquiry. Instead of directly addressing the issue, division officials indicated that another department within the DOJ would be better suited to review the concerns. They subsequently referred the matter to the FBI’s inspection division.

Sterling expressed concern that the delayed response signified a lack of capacity within the DOJ’s investigative body, potentially compromising its ability to handle more serious cases of misconduct. The delay is noteworthy because it could impact the accuracy of the FBI’s annual uniform crime report. With more than a year already passed, there’s a risk that the report will continue to inaccurately represent the changes in cannabis policy happening across the nation.

This situation is particularly relevant in areas that have decriminalized marijuana, where possession might lead to civil penalties but is not meant to result in an arrest. By wrongly categorizing these instances as arrests, the impact of policy changes could be understated or even misrepresented as an increase in crime.

Furthermore, the reliability of the FBI’s cannabis enforcement reporting is questionable because local and state police aren’t obligated to share their data with the agency. This results in an incomplete overview of law enforcement activities on a national scale. The latest quarterly report had data from only 12,518 out of 18,900 law enforcement agencies in the country.

Despite these reporting concerns, recent trends have generally aligned with expectations. The FBI’s data shows a decrease in cannabis-related arrests as more states have embraced legalization. Even the DEA reported fewer marijuana-related arrests in the previous year, while the agency’s eradication of cannabis plants increased.

Customs and Border Protection data from the past fiscal year also revealed a record low in cannabis seizures. A report from the Government Accountability Office echoed these trends, illustrating that enforcement activities are primarily targeting small amounts of marijuana possessed by U.S. citizens rather than large shipments from international sources.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Alternative Products Expo: Innovation and Sustainability

Financial analysts, savvy investors, business owners, researchers, and pioneers, are invited to attend Alternative Products Expo to be held at the World Market Center, Las Vegas from September 14-16, 2023. Las Vegas plays host to thousands of esteemed events every year, and there are several reasons for this: state-of-the-art hospitality, top-notch facilities, year-round sunshine, and world-class dining and entertainment options. Featuring one-of-a-kind nightlife, the city never fails to provide a memorable experience for the attendees.

Alternative Products Expo (AltPro Expo) promises to deliver unique networking opportunities for customers and businesses alike. The highly anticipated event has earned a reputation for offering an incredible platform for business owners to showcase their unique and sustainable products. As the countdown for this innovative Expo begins, attendees can expect an unmatched experience packed with actionable insights from the industry leaders.

Exciting Opportunities for Forward-Thinking Businesses

Pioneered by a group of socially responsible entrepreneurs, the Alternative Products Expo is committed to connecting revolutionary businesses with health-conscious customers. The expo will feature a wide range of eco-friendly and innovative products, ranging from plant-based foods, and renewable energy technologies, to sustainable packaging solutions and ethical fashion items. They will witness innovative demos and learn of the latest product launches that will shape a sustainable future and reduce the environmental footprint at a global level.

The AltPro Expo provides customers with a unique opportunity to buy products that contribute to an eco-friendly planet. The organizers will implement sustainable practices throughout the Expo to ensure the targeted audience aligns with their values. Attendees will get a unique opportunity to network with like-minded entrepreneurs and potential investors who will share their passion for innovation. By attending thought-provoking seminars and panel discussions, they will get insights into the latest trends and best practices in the alternative products industry.

To learn more, please visit https://cnw.fm/A8zIE.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Study Finds Psychosis-Prone Young People Registered Surprising Symptom Improvement After Using Marijuana

A team of researchers from several institutions has discovered that cannabis may improve symptoms in teenagers and young adults at risk of developing psychosis. The study contradicts claims that marijuana use can trigger the early onset of psychotic disorder symptoms and shows that cannabis may actually deliver modest cognitive functioning improvements while reducing the use of prescribed medications.

Researchers at the Stanford University School of Medicine, Zucker Hillside Hospital, University of California at Davis and the University of Michigan published their findings in the “Psychiatry Research” journal. The study noted that the recent surge in recreational cannabis use has raised questions regarding the possibility of adult use being a trigger for the onset of psychosis.

However, the study authors note that there is little evidence tying cannabis use and negative health outcomes for people who are predisposed to developing psychosis.

The research team followed 210 patients with a clinical high risk (CHR) of psychosis who took part in an Early Detection and Intervention for the Prevention of Psychosis Program (EDIPPP) for two years. Over the study period, the researchers compared prescription medication use with mental health in people who consumed cannabis regularly and people who didn’t consume cannabis.

Individuals who consumed cannabis continually over the two-year study period did not exhibit an increased psychosis transition rate, study authors say, and cannabis use did not contribute to a decline in clinical symptoms, neurocognition or functioning levels. On the contrary, youth who used cannabis continuously exhibited improved clinical symptoms even as their medication use decreased.

Furthermore, the scientists found that CHR youth who used cannabis regularly over the study period had higher social functioning and neurocognition compared to noncannabis users. The recent study adds to the growing body of scientific literature on cannabis and its potential association with psychosis.

Cannabis legalization opponents have long claimed that cannabis use can trigger schizophrenia, especially now that the market is flooded with increasingly potent THC-infused products. Some medical professionals have also stated that continued exposure to high-THC cannabis may cause psychosis-like symptoms in some consumers.

Studies have found that cannabis-induced psychosis is quite rare, with a Canadian study that analyzed 23,000 consumers finding that only 26 individuals required hospitalization for psychotic-like symptoms. Data from Canada also shows that although the country legalized adult-use cannabis in 2018, there has been no significant increase in the number of emergency room visits due to cannabis-induced schizophrenia or psychosis.

Additionally, a European study published in the “Translation Psychiatry” journal found that less than one-half of 1% of 230,000 consumers experienced psychosis-like symptoms after consuming cannabis.

As the different misconceptions about marijuana are dispelled one at a time, demand for the substance is likely to increase and enterprises such as Advanced Container Technologies Inc. (OTC: ACTX), which capitalize on availing some of the products that marijuana cultivators need, could grow their businesses.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.